| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Transplantation | 84 | 2021 | 849 | 6.620 |
Why?
|
| Living Donors | 25 | 2021 | 339 | 4.210 |
Why?
|
| Graft Rejection | 82 | 2005 | 1065 | 2.990 |
Why?
|
| Tissue and Organ Procurement | 20 | 2019 | 311 | 2.740 |
Why?
|
| Immunosuppressive Agents | 45 | 2004 | 977 | 2.300 |
Why?
|
| Liver Transplantation | 60 | 2018 | 1268 | 2.170 |
Why?
|
| Pancreas Transplantation | 21 | 2006 | 103 | 2.010 |
Why?
|
| Graft Survival | 58 | 2016 | 884 | 2.010 |
Why?
|
| Tacrolimus | 24 | 2004 | 373 | 1.760 |
Why?
|
| Muromonab-CD3 | 26 | 1999 | 69 | 1.550 |
Why?
|
| Tissue Donors | 25 | 2016 | 463 | 1.350 |
Why?
|
| Kidney Failure, Chronic | 9 | 2014 | 509 | 1.340 |
Why?
|
| Physician-Patient Relations | 6 | 2015 | 610 | 1.220 |
Why?
|
| Antibodies, Monoclonal | 37 | 2001 | 1376 | 1.130 |
Why?
|
| Decision Making | 7 | 2015 | 642 | 1.070 |
Why?
|
| Informed Consent | 9 | 2021 | 266 | 1.070 |
Why?
|
| Transplantation, Homologous | 38 | 2005 | 996 | 0.970 |
Why?
|
| Attitude of Health Personnel | 9 | 2015 | 636 | 0.840 |
Why?
|
| Waiting Lists | 6 | 2015 | 175 | 0.840 |
Why?
|
| Organ Transplantation | 4 | 2016 | 265 | 0.830 |
Why?
|
| Cyclosporine | 18 | 2004 | 234 | 0.820 |
Why?
|
| Humans | 192 | 2021 | 86617 | 0.740 |
Why?
|
| Racism | 1 | 2021 | 81 | 0.690 |
Why?
|
| Transplantation, Heterologous | 10 | 1997 | 363 | 0.680 |
Why?
|
| Personal Autonomy | 3 | 2018 | 112 | 0.680 |
Why?
|
| Islets of Langerhans Transplantation | 12 | 1999 | 225 | 0.660 |
Why?
|
| General Practice | 2 | 2015 | 8 | 0.640 |
Why?
|
| Ethics, Research | 1 | 2018 | 52 | 0.630 |
Why?
|
| Education, Medical, Undergraduate | 2 | 2013 | 160 | 0.590 |
Why?
|
| Kidney | 14 | 2016 | 1241 | 0.570 |
Why?
|
| Time Factors | 35 | 2015 | 5209 | 0.570 |
Why?
|
| Social Justice | 2 | 2018 | 49 | 0.570 |
Why?
|
| Diabetes Mellitus, Experimental | 9 | 1999 | 190 | 0.550 |
Why?
|
| Patient Selection | 7 | 2018 | 685 | 0.540 |
Why?
|
| Patient Portals | 1 | 2015 | 15 | 0.530 |
Why?
|
| Patient Participation | 4 | 2011 | 216 | 0.520 |
Why?
|
| Health Services Accessibility | 2 | 2015 | 394 | 0.510 |
Why?
|
| Risk Assessment | 8 | 2018 | 2261 | 0.500 |
Why?
|
| Biomedical Research | 1 | 2018 | 375 | 0.480 |
Why?
|
| Healthcare Disparities | 2 | 2015 | 370 | 0.480 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2014 | 78 | 0.470 |
Why?
|
| Registries | 2 | 2007 | 702 | 0.470 |
Why?
|
| Adult | 67 | 2019 | 25640 | 0.430 |
Why?
|
| Efficiency, Organizational | 1 | 2012 | 58 | 0.420 |
Why?
|
| Genetic Testing | 1 | 2016 | 535 | 0.420 |
Why?
|
| Coercion | 1 | 2012 | 15 | 0.420 |
Why?
|
| T-Lymphocytes | 19 | 2001 | 1195 | 0.420 |
Why?
|
| Clinical Clerkship | 1 | 2013 | 116 | 0.410 |
Why?
|
| Moral Obligations | 1 | 2012 | 52 | 0.410 |
Why?
|
| Surgery, Plastic | 1 | 2012 | 42 | 0.410 |
Why?
|
| Education, Professional | 1 | 2011 | 2 | 0.400 |
Why?
|
| Professional Misconduct | 1 | 2011 | 25 | 0.390 |
Why?
|
| Accreditation | 1 | 2011 | 60 | 0.380 |
Why?
|
| Ethics, Medical | 6 | 2016 | 306 | 0.380 |
Why?
|
| Male | 65 | 2019 | 40958 | 0.380 |
Why?
|
| Decision Support Systems, Clinical | 2 | 2011 | 103 | 0.380 |
Why?
|
| Decision Support Techniques | 2 | 2015 | 160 | 0.370 |
Why?
|
| Health Behavior | 3 | 2016 | 183 | 0.370 |
Why?
|
| Family Practice | 3 | 2006 | 84 | 0.370 |
Why?
|
| Immunoconjugates | 9 | 2001 | 106 | 0.370 |
Why?
|
| Mycophenolic Acid | 3 | 1998 | 87 | 0.350 |
Why?
|
| Adolescent | 33 | 2016 | 8979 | 0.350 |
Why?
|
| Female | 65 | 2021 | 44509 | 0.340 |
Why?
|
| Burnout, Professional | 1 | 2011 | 94 | 0.340 |
Why?
|
| Health Personnel | 1 | 2011 | 202 | 0.340 |
Why?
|
| Child | 36 | 2016 | 6926 | 0.330 |
Why?
|
| Attitude to Health | 3 | 2008 | 220 | 0.330 |
Why?
|
| Antilymphocyte Serum | 13 | 1998 | 71 | 0.330 |
Why?
|
| Intestine, Small | 6 | 2001 | 303 | 0.320 |
Why?
|
| Middle Aged | 40 | 2019 | 25017 | 0.310 |
Why?
|
| Postoperative Complications | 20 | 2001 | 2207 | 0.310 |
Why?
|
| Students, Medical | 2 | 2011 | 384 | 0.310 |
Why?
|
| United States | 13 | 2021 | 6665 | 0.310 |
Why?
|
| Cadaver | 12 | 2012 | 185 | 0.300 |
Why?
|
| Age Factors | 13 | 2015 | 1849 | 0.300 |
Why?
|
| Portal Vein | 7 | 2000 | 120 | 0.300 |
Why?
|
| Histocompatibility Antigens Class II | 6 | 1999 | 158 | 0.300 |
Why?
|
| Referral and Consultation | 2 | 2007 | 326 | 0.300 |
Why?
|
| Medical Staff, Hospital | 2 | 2010 | 107 | 0.280 |
Why?
|
| Reoperation | 20 | 2002 | 597 | 0.280 |
Why?
|
| Internet | 2 | 2010 | 312 | 0.280 |
Why?
|
| B7-1 Antigen | 4 | 2001 | 75 | 0.270 |
Why?
|
| Education, Medical, Graduate | 2 | 2007 | 369 | 0.270 |
Why?
|
| Transplantation, Isogeneic | 5 | 1999 | 39 | 0.260 |
Why?
|
| State Medicine | 1 | 2005 | 12 | 0.260 |
Why?
|
| Lymphoproliferative Disorders | 5 | 2001 | 107 | 0.260 |
Why?
|
| Algorithms | 3 | 2015 | 1830 | 0.260 |
Why?
|
| Truth Disclosure | 2 | 2015 | 87 | 0.260 |
Why?
|
| Child, Preschool | 27 | 2013 | 3611 | 0.260 |
Why?
|
| Histocompatibility Testing | 7 | 1999 | 154 | 0.250 |
Why?
|
| Skin Transplantation | 6 | 2000 | 172 | 0.250 |
Why?
|
| Follow-Up Studies | 25 | 2006 | 3636 | 0.250 |
Why?
|
| Transplant Recipients | 2 | 2015 | 122 | 0.240 |
Why?
|
| Duodenum | 3 | 2006 | 100 | 0.240 |
Why?
|
| Cyclosporins | 9 | 1990 | 59 | 0.240 |
Why?
|
| Resource Allocation | 2 | 2011 | 65 | 0.240 |
Why?
|
| CD3 Complex | 9 | 1995 | 135 | 0.240 |
Why?
|
| Drug Therapy | 1 | 2003 | 70 | 0.230 |
Why?
|
| Lymphocyte Activation | 14 | 2001 | 728 | 0.230 |
Why?
|
| Azathioprine | 12 | 1998 | 125 | 0.230 |
Why?
|
| Risk | 4 | 2016 | 674 | 0.230 |
Why?
|
| Organ Preservation | 8 | 1996 | 83 | 0.230 |
Why?
|
| Cytokines | 4 | 1999 | 776 | 0.220 |
Why?
|
| Antigens, Differentiation | 10 | 2001 | 141 | 0.220 |
Why?
|
| Low Back Pain | 2 | 2014 | 40 | 0.220 |
Why?
|
| Survival Rate | 13 | 1998 | 1860 | 0.210 |
Why?
|
| Infant | 20 | 2000 | 3045 | 0.210 |
Why?
|
| Antigens, CD | 14 | 2001 | 458 | 0.210 |
Why?
|
| Mice, SCID | 6 | 2000 | 252 | 0.210 |
Why?
|
| Biopsy | 11 | 2005 | 1162 | 0.200 |
Why?
|
| Recombinant Fusion Proteins | 4 | 2000 | 557 | 0.200 |
Why?
|
| Heart Transplantation | 5 | 2001 | 705 | 0.200 |
Why?
|
| Tumor Virus Infections | 3 | 2002 | 81 | 0.200 |
Why?
|
| CD28 Antigens | 5 | 2001 | 88 | 0.190 |
Why?
|
| Policy Making | 2 | 2018 | 62 | 0.190 |
Why?
|
| Prednisone | 11 | 1998 | 258 | 0.190 |
Why?
|
| Creatinine | 8 | 1999 | 338 | 0.190 |
Why?
|
| Mice | 28 | 2001 | 11352 | 0.180 |
Why?
|
| Family | 4 | 2014 | 311 | 0.180 |
Why?
|
| Receptors, Fc | 2 | 1999 | 33 | 0.180 |
Why?
|
| Program Evaluation | 3 | 2013 | 297 | 0.180 |
Why?
|
| Diabetes Complications | 2 | 2000 | 207 | 0.180 |
Why?
|
| Coronary Circulation | 1 | 2000 | 130 | 0.180 |
Why?
|
| Methylprednisolone | 7 | 1997 | 66 | 0.180 |
Why?
|
| Animals | 45 | 2001 | 26582 | 0.170 |
Why?
|
| Netherlands | 1 | 2019 | 19 | 0.170 |
Why?
|
| Lymphocyte Transfusion | 3 | 2000 | 41 | 0.170 |
Why?
|
| Transplantation | 2 | 1997 | 39 | 0.170 |
Why?
|
| Peptide Fragments | 2 | 2005 | 460 | 0.170 |
Why?
|
| Steroids | 2 | 1998 | 177 | 0.160 |
Why?
|
| Mice, Inbred C57BL | 15 | 2001 | 3092 | 0.160 |
Why?
|
| Beneficence | 1 | 2018 | 33 | 0.160 |
Why?
|
| Maple Syrup Urine Disease | 1 | 2018 | 5 | 0.160 |
Why?
|
| Ethical Analysis | 1 | 2018 | 23 | 0.160 |
Why?
|
| Acute Disease | 8 | 2003 | 826 | 0.160 |
Why?
|
| United Kingdom | 2 | 2011 | 164 | 0.160 |
Why?
|
| Enterococcus | 1 | 1998 | 35 | 0.160 |
Why?
|
| Herpesvirus 4, Human | 3 | 2001 | 114 | 0.160 |
Why?
|
| CD8-Positive T-Lymphocytes | 6 | 2001 | 559 | 0.160 |
Why?
|
| Proportional Hazards Models | 4 | 2016 | 858 | 0.160 |
Why?
|
| Australia | 2 | 2015 | 99 | 0.160 |
Why?
|
| Capillaries | 3 | 2005 | 91 | 0.160 |
Why?
|
| Research Subjects | 1 | 2018 | 73 | 0.160 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 1998 | 47 | 0.150 |
Why?
|
| Vancomycin | 1 | 1998 | 72 | 0.150 |
Why?
|
| HLA Antigens | 3 | 1997 | 232 | 0.150 |
Why?
|
| Transplantation, Heterotopic | 2 | 1995 | 45 | 0.150 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2013 | 508 | 0.150 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 1997 | 100 | 0.150 |
Why?
|
| Retrospective Studies | 20 | 1999 | 8477 | 0.150 |
Why?
|
| Rats, Inbred Lew | 6 | 1995 | 186 | 0.150 |
Why?
|
| Pilot Projects | 5 | 2014 | 839 | 0.150 |
Why?
|
| Transplantation Chimera | 1 | 1996 | 80 | 0.140 |
Why?
|
| Hepatectomy | 6 | 1996 | 166 | 0.140 |
Why?
|
| Risk Factors | 14 | 2018 | 5417 | 0.140 |
Why?
|
| Major Histocompatibility Complex | 5 | 1995 | 81 | 0.140 |
Why?
|
| Rats | 13 | 1995 | 3990 | 0.140 |
Why?
|
| Apolipoprotein L1 | 1 | 2016 | 7 | 0.140 |
Why?
|
| Receptors, Antigen, T-Cell | 8 | 2001 | 372 | 0.140 |
Why?
|
| Drug Therapy, Combination | 12 | 2004 | 894 | 0.140 |
Why?
|
| Immunotherapy | 1 | 2001 | 629 | 0.140 |
Why?
|
| Diseases in Twins | 1 | 2016 | 65 | 0.140 |
Why?
|
| Diabetes Mellitus, Type 1 | 4 | 2006 | 567 | 0.140 |
Why?
|
| Actins | 1 | 1999 | 451 | 0.140 |
Why?
|
| International Cooperation | 1 | 2016 | 127 | 0.140 |
Why?
|
| Disclosure | 1 | 2016 | 108 | 0.140 |
Why?
|
| Islets of Langerhans | 3 | 1995 | 544 | 0.130 |
Why?
|
| Congresses as Topic | 1 | 2016 | 116 | 0.130 |
Why?
|
| Treatment Outcome | 13 | 2015 | 7990 | 0.130 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 7 | 1994 | 95 | 0.130 |
Why?
|
| CD4-Positive T-Lymphocytes | 6 | 2001 | 425 | 0.130 |
Why?
|
| Diabetes Mellitus | 2 | 2004 | 806 | 0.130 |
Why?
|
| History, 20th Century | 1 | 2016 | 312 | 0.130 |
Why?
|
| Liver | 12 | 2014 | 1230 | 0.130 |
Why?
|
| Glomerulonephritis, Membranous | 1 | 1994 | 24 | 0.130 |
Why?
|
| C-Peptide | 3 | 1999 | 174 | 0.130 |
Why?
|
| Aged | 13 | 2015 | 18402 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2015 | 860 | 0.120 |
Why?
|
| Health Policy | 1 | 2016 | 180 | 0.120 |
Why?
|
| Geography | 1 | 2015 | 223 | 0.120 |
Why?
|
| Physicians | 3 | 2014 | 673 | 0.120 |
Why?
|
| Jejunum | 3 | 2006 | 79 | 0.120 |
Why?
|
| Crigler-Najjar Syndrome | 1 | 1993 | 3 | 0.120 |
Why?
|
| Health Equity | 1 | 2015 | 77 | 0.120 |
Why?
|
| Patient Satisfaction | 2 | 2014 | 454 | 0.120 |
Why?
|
| Intestines | 4 | 2001 | 411 | 0.120 |
Why?
|
| Mice, Knockout | 9 | 2001 | 1924 | 0.120 |
Why?
|
| End Stage Liver Disease | 1 | 2014 | 61 | 0.120 |
Why?
|
| Patient Preference | 1 | 2014 | 105 | 0.120 |
Why?
|
| Continuity of Patient Care | 1 | 2015 | 169 | 0.120 |
Why?
|
| Survival Analysis | 7 | 2000 | 1538 | 0.120 |
Why?
|
| Bone Marrow Transplantation | 1 | 1994 | 286 | 0.110 |
Why?
|
| Patient Education as Topic | 2 | 2006 | 351 | 0.110 |
Why?
|
| Health Status | 1 | 2015 | 360 | 0.110 |
Why?
|
| England | 2 | 2003 | 41 | 0.110 |
Why?
|
| Behavior | 1 | 2013 | 85 | 0.110 |
Why?
|
| CD8 Antigens | 5 | 1999 | 82 | 0.110 |
Why?
|
| Peer Group | 1 | 2013 | 72 | 0.110 |
Why?
|
| Mice, Inbred C3H | 8 | 2001 | 370 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 3 | 2016 | 1034 | 0.110 |
Why?
|
| B-Lymphocytes | 3 | 1990 | 724 | 0.110 |
Why?
|
| Reproducibility of Results | 2 | 2011 | 2705 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 1 | 1998 | 746 | 0.110 |
Why?
|
| Drainage | 4 | 1998 | 157 | 0.110 |
Why?
|
| Mentors | 1 | 2013 | 76 | 0.110 |
Why?
|
| Nephritis, Interstitial | 3 | 2002 | 47 | 0.110 |
Why?
|
| HLA-D Antigens | 2 | 1995 | 20 | 0.110 |
Why?
|
| Insulin | 4 | 1999 | 1160 | 0.110 |
Why?
|
| Career Choice | 1 | 2013 | 139 | 0.100 |
Why?
|
| Prospective Studies | 6 | 2016 | 4212 | 0.100 |
Why?
|
| Residence Characteristics | 1 | 2013 | 197 | 0.100 |
Why?
|
| Biopsy, Needle | 3 | 1998 | 235 | 0.100 |
Why?
|
| Data Interpretation, Statistical | 1 | 2013 | 297 | 0.100 |
Why?
|
| Educational Measurement | 1 | 2013 | 225 | 0.100 |
Why?
|
| RNA, Messenger | 3 | 2001 | 1981 | 0.100 |
Why?
|
| Surveys and Questionnaires | 5 | 2015 | 2501 | 0.100 |
Why?
|
| Surgeons | 1 | 2015 | 238 | 0.100 |
Why?
|
| Genotype | 1 | 2016 | 1851 | 0.100 |
Why?
|
| Recurrence | 5 | 1998 | 1139 | 0.100 |
Why?
|
| Siblings | 2 | 2008 | 111 | 0.100 |
Why?
|
| Abatacept | 9 | 2001 | 83 | 0.100 |
Why?
|
| Prescriptions | 1 | 2010 | 21 | 0.100 |
Why?
|
| Focus Groups | 2 | 2010 | 155 | 0.100 |
Why?
|
| Cross-Cultural Comparison | 1 | 2010 | 34 | 0.100 |
Why?
|
| Pancreas | 7 | 1999 | 239 | 0.100 |
Why?
|
| Professional Competence | 1 | 2011 | 68 | 0.100 |
Why?
|
| Biliary Tract Diseases | 3 | 1997 | 34 | 0.100 |
Why?
|
| Infant, Newborn | 4 | 1998 | 2378 | 0.100 |
Why?
|
| CTLA-4 Antigen | 9 | 2001 | 135 | 0.090 |
Why?
|
| Lymphocyte Culture Test, Mixed | 5 | 1997 | 74 | 0.090 |
Why?
|
| Blood Glucose | 5 | 1996 | 873 | 0.090 |
Why?
|
| Physical Therapy Modalities | 1 | 2011 | 84 | 0.090 |
Why?
|
| Directed Tissue Donation | 2 | 2006 | 7 | 0.090 |
Why?
|
| Learning | 1 | 2013 | 280 | 0.090 |
Why?
|
| Immune Tolerance | 4 | 2001 | 337 | 0.090 |
Why?
|
| Health Services Needs and Demand | 1 | 2010 | 102 | 0.090 |
Why?
|
| Renal Veins | 1 | 1989 | 28 | 0.090 |
Why?
|
| Choice Behavior | 1 | 2011 | 160 | 0.090 |
Why?
|
| Transplantation Tolerance | 2 | 2001 | 130 | 0.090 |
Why?
|
| Influenza Vaccines | 1 | 2010 | 142 | 0.090 |
Why?
|
| Drug Resistance | 5 | 1996 | 256 | 0.090 |
Why?
|
| Costs and Cost Analysis | 3 | 1997 | 153 | 0.090 |
Why?
|
| Renal Artery | 1 | 1989 | 64 | 0.080 |
Why?
|
| Arteriovenous Fistula | 1 | 1989 | 52 | 0.080 |
Why?
|
| Cytomegalovirus Infections | 4 | 1996 | 144 | 0.080 |
Why?
|
| Young Adult | 3 | 2015 | 5974 | 0.080 |
Why?
|
| Liver Function Tests | 4 | 1997 | 93 | 0.080 |
Why?
|
| Chicago | 6 | 2000 | 1379 | 0.080 |
Why?
|
| Minors | 1 | 2008 | 15 | 0.080 |
Why?
|
| Palpation | 1 | 2008 | 18 | 0.080 |
Why?
|
| Parental Consent | 1 | 2008 | 35 | 0.080 |
Why?
|
| Drug Administration Schedule | 5 | 1998 | 916 | 0.080 |
Why?
|
| Mice, Inbred Strains | 5 | 2000 | 307 | 0.080 |
Why?
|
| Veins | 1 | 1988 | 94 | 0.080 |
Why?
|
| Genes, MHC Class II | 3 | 1998 | 30 | 0.080 |
Why?
|
| Hot Temperature | 1 | 1989 | 206 | 0.080 |
Why?
|
| Physicians, Family | 1 | 2008 | 40 | 0.080 |
Why?
|
| Professional Practice | 1 | 2008 | 46 | 0.080 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2010 | 581 | 0.080 |
Why?
|
| Swine | 4 | 1984 | 555 | 0.080 |
Why?
|
| Lymphocytes | 2 | 1995 | 464 | 0.080 |
Why?
|
| Trans-Activators | 2 | 2001 | 429 | 0.080 |
Why?
|
| Education, Medical | 1 | 2011 | 233 | 0.080 |
Why?
|
| Pelvis | 1 | 2008 | 95 | 0.080 |
Why?
|
| Histocompatibility Antigens Class I | 4 | 1999 | 203 | 0.080 |
Why?
|
| Swine, Miniature | 2 | 1984 | 51 | 0.080 |
Why?
|
| Clinical Competence | 1 | 2013 | 751 | 0.080 |
Why?
|
| Arteries | 1 | 1988 | 176 | 0.080 |
Why?
|
| ABO Blood-Group System | 2 | 2006 | 62 | 0.080 |
Why?
|
| Social Responsibility | 1 | 2007 | 57 | 0.080 |
Why?
|
| Immunoglobulin G | 5 | 1997 | 456 | 0.080 |
Why?
|
| Confidentiality | 3 | 2015 | 78 | 0.080 |
Why?
|
| Monitoring, Physiologic | 2 | 1989 | 268 | 0.080 |
Why?
|
| Influenza, Human | 1 | 2010 | 329 | 0.080 |
Why?
|
| Flow Cytometry | 5 | 1994 | 679 | 0.070 |
Why?
|
| Cryopreservation | 3 | 1996 | 68 | 0.070 |
Why?
|
| Antigens, Surface | 1 | 1987 | 101 | 0.070 |
Why?
|
| Curriculum | 2 | 2010 | 539 | 0.070 |
Why?
|
| Hematopoietic Stem Cells | 1 | 1989 | 292 | 0.070 |
Why?
|
| Embolization, Therapeutic | 1 | 1989 | 238 | 0.070 |
Why?
|
| Interviews as Topic | 1 | 2007 | 319 | 0.070 |
Why?
|
| Interleukin-2 | 5 | 2000 | 249 | 0.070 |
Why?
|
| Bilirubin | 2 | 1998 | 125 | 0.070 |
Why?
|
| Tumor Necrosis Factor-alpha | 6 | 2001 | 683 | 0.070 |
Why?
|
| Histocompatibility | 1 | 2006 | 71 | 0.070 |
Why?
|
| Data Collection | 3 | 2014 | 372 | 0.070 |
Why?
|
| Incidence | 7 | 1998 | 1577 | 0.070 |
Why?
|
| Prognosis | 5 | 2011 | 3675 | 0.070 |
Why?
|
| Liver Diseases | 4 | 1991 | 238 | 0.070 |
Why?
|
| Attitude | 2 | 2016 | 127 | 0.070 |
Why?
|
| Hepatic Artery | 3 | 1996 | 83 | 0.060 |
Why?
|
| Iliac Vein | 2 | 1996 | 30 | 0.060 |
Why?
|
| Complement C4b | 1 | 2005 | 35 | 0.060 |
Why?
|
| Transplantation Immunology | 2 | 1997 | 84 | 0.060 |
Why?
|
| Calcium Channel Agonists | 1 | 2004 | 13 | 0.060 |
Why?
|
| Treatment Failure | 2 | 1997 | 285 | 0.060 |
Why?
|
| Intraoperative Care | 3 | 1989 | 82 | 0.060 |
Why?
|
| Minority Groups | 1 | 2006 | 137 | 0.060 |
Why?
|
| Hospitals, University | 3 | 1997 | 194 | 0.060 |
Why?
|
| Therapeutic Human Experimentation | 2 | 1997 | 20 | 0.060 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2004 | 33 | 0.060 |
Why?
|
| Urinary Bladder | 2 | 1996 | 246 | 0.060 |
Why?
|
| Multivariate Analysis | 2 | 2015 | 999 | 0.060 |
Why?
|
| Thrombosis | 3 | 1998 | 296 | 0.060 |
Why?
|
| Patient-Centered Care | 1 | 2006 | 202 | 0.060 |
Why?
|
| Calcitriol | 1 | 2004 | 174 | 0.060 |
Why?
|
| Anastomosis, Surgical | 5 | 2006 | 267 | 0.060 |
Why?
|
| Dendritic Cells | 1 | 1987 | 425 | 0.060 |
Why?
|
| Models, Theoretical | 1 | 2006 | 482 | 0.060 |
Why?
|
| Antibodies, Anti-Idiotypic | 4 | 1991 | 44 | 0.060 |
Why?
|
| Surgical Wound Infection | 4 | 1998 | 184 | 0.060 |
Why?
|
| Th1 Cells | 2 | 2001 | 164 | 0.060 |
Why?
|
| Th2 Cells | 2 | 2001 | 146 | 0.060 |
Why?
|
| Blood Platelets | 1 | 2003 | 149 | 0.060 |
Why?
|
| Actuarial Analysis | 3 | 1997 | 66 | 0.060 |
Why?
|
| Schools, Medical | 1 | 2003 | 123 | 0.050 |
Why?
|
| BK Virus | 1 | 2002 | 23 | 0.050 |
Why?
|
| Hypovolemia | 1 | 2001 | 3 | 0.050 |
Why?
|
| Polyomavirus Infections | 1 | 2002 | 28 | 0.050 |
Why?
|
| Patient Compliance | 1 | 2003 | 227 | 0.050 |
Why?
|
| Cytomegalovirus | 2 | 1995 | 76 | 0.050 |
Why?
|
| Academic Medical Centers | 2 | 2014 | 379 | 0.050 |
Why?
|
| Receptors, Interleukin-2 | 5 | 1994 | 66 | 0.050 |
Why?
|
| Lymphotoxin-alpha | 1 | 2001 | 44 | 0.050 |
Why?
|
| Kidney Glomerulus | 2 | 2003 | 123 | 0.050 |
Why?
|
| Calcium | 2 | 2004 | 1156 | 0.050 |
Why?
|
| Biological Availability | 2 | 1998 | 92 | 0.050 |
Why?
|
| Risk-Taking | 1 | 2002 | 148 | 0.050 |
Why?
|
| CD40 Antigens | 1 | 2001 | 43 | 0.050 |
Why?
|
| Methylprednisolone Hemisuccinate | 2 | 1998 | 10 | 0.050 |
Why?
|
| CD40 Ligand | 1 | 2001 | 69 | 0.050 |
Why?
|
| Therapeutic Equivalency | 1 | 2000 | 12 | 0.050 |
Why?
|
| Consumer Product Safety | 1 | 2000 | 11 | 0.050 |
Why?
|
| Quality Assurance, Health Care | 1 | 2002 | 220 | 0.050 |
Why?
|
| Pediatrics | 3 | 2008 | 344 | 0.050 |
Why?
|
| Blood Transfusion | 3 | 1999 | 157 | 0.050 |
Why?
|
| Antibodies, Viral | 2 | 1995 | 293 | 0.050 |
Why?
|
| Femoral Vein | 2 | 1999 | 35 | 0.050 |
Why?
|
| Plasma Cells | 1 | 2001 | 80 | 0.050 |
Why?
|
| Length of Stay | 2 | 1997 | 700 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 1999 | 376 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2000 | 159 | 0.050 |
Why?
|
| Analysis of Variance | 3 | 1998 | 912 | 0.050 |
Why?
|
| Immunoenzyme Techniques | 3 | 2003 | 303 | 0.050 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 1999 | 17 | 0.050 |
Why?
|
| Half-Life | 1 | 1999 | 96 | 0.040 |
Why?
|
| Arterioles | 1 | 1999 | 22 | 0.040 |
Why?
|
| Recombinant Proteins | 2 | 2000 | 1014 | 0.040 |
Why?
|
| Rats, Inbred Strains | 3 | 1989 | 312 | 0.040 |
Why?
|
| Ischemia | 3 | 1996 | 243 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 1999 | 1961 | 0.040 |
Why?
|
| Gallbladder | 2 | 1997 | 30 | 0.040 |
Why?
|
| Ganciclovir | 2 | 1997 | 49 | 0.040 |
Why?
|
| Protein Isoforms | 1 | 2000 | 270 | 0.040 |
Why?
|
| Signal Transduction | 5 | 2001 | 3241 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 2 | 1998 | 263 | 0.040 |
Why?
|
| Postoperative Care | 1 | 1999 | 221 | 0.040 |
Why?
|
| Volition | 1 | 2018 | 15 | 0.040 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 1999 | 231 | 0.040 |
Why?
|
| Hemoperfusion | 2 | 1988 | 5 | 0.040 |
Why?
|
| Glucocorticoids | 2 | 1997 | 352 | 0.040 |
Why?
|
| Drug Resistance, Microbial | 1 | 1998 | 72 | 0.040 |
Why?
|
| Communication | 1 | 2002 | 441 | 0.040 |
Why?
|
| Gallbladder Diseases | 1 | 1998 | 22 | 0.040 |
Why?
|
| Spleen | 2 | 2000 | 430 | 0.040 |
Why?
|
| Genes, T-Cell Receptor beta | 1 | 1997 | 8 | 0.040 |
Why?
|
| Intercellular Adhesion Molecule-1 | 2 | 1994 | 71 | 0.040 |
Why?
|
| Membrane Glycoproteins | 2 | 2001 | 428 | 0.040 |
Why?
|
| DNA-Binding Proteins | 2 | 2001 | 1208 | 0.040 |
Why?
|
| Perfusion | 2 | 1989 | 203 | 0.040 |
Why?
|
| Human Body | 1 | 1997 | 6 | 0.040 |
Why?
|
| Anti-Inflammatory Agents | 2 | 1997 | 339 | 0.040 |
Why?
|
| Complement C3 | 1 | 1997 | 58 | 0.040 |
Why?
|
| Urinary Retention | 1 | 1997 | 40 | 0.040 |
Why?
|
| Quality of Life | 2 | 1996 | 1583 | 0.040 |
Why?
|
| Femoral Neoplasms | 1 | 1997 | 24 | 0.040 |
Why?
|
| Nephrectomy | 3 | 2008 | 294 | 0.040 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 1997 | 19 | 0.040 |
Why?
|
| Digestive System Surgical Procedures | 1 | 1998 | 120 | 0.040 |
Why?
|
| Chondrosarcoma | 1 | 1997 | 48 | 0.040 |
Why?
|
| Amylases | 2 | 1994 | 13 | 0.040 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2001 | 272 | 0.040 |
Why?
|
| Fibrin | 1 | 1997 | 84 | 0.040 |
Why?
|
| Bone Transplantation | 1 | 1997 | 64 | 0.040 |
Why?
|
| Preoperative Care | 1 | 1999 | 394 | 0.040 |
Why?
|
| Myocardium | 1 | 2000 | 529 | 0.040 |
Why?
|
| Renal Insufficiency | 1 | 1998 | 114 | 0.040 |
Why?
|
| Bacteremia | 1 | 1998 | 99 | 0.040 |
Why?
|
| Occlusive Dressings | 1 | 1996 | 7 | 0.040 |
Why?
|
| Ileum | 1 | 1997 | 159 | 0.040 |
Why?
|
| Biliary Atresia | 3 | 1992 | 22 | 0.040 |
Why?
|
| Chronic Disease | 2 | 1999 | 971 | 0.040 |
Why?
|
| Polytetrafluoroethylene | 1 | 1996 | 74 | 0.040 |
Why?
|
| Fractures, Bone | 1 | 1998 | 131 | 0.040 |
Why?
|
| Homozygote | 1 | 1996 | 200 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2000 | 864 | 0.040 |
Why?
|
| Respiratory Insufficiency | 1 | 1998 | 150 | 0.030 |
Why?
|
| Hospitalization | 1 | 2002 | 849 | 0.030 |
Why?
|
| Graft Occlusion, Vascular | 1 | 1996 | 99 | 0.030 |
Why?
|
| Neutrophils | 1 | 1997 | 307 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 257 | 0.030 |
Why?
|
| Cold Temperature | 3 | 1996 | 157 | 0.030 |
Why?
|
| Bone Diseases | 1 | 1995 | 54 | 0.030 |
Why?
|
| Italy | 1 | 2015 | 106 | 0.030 |
Why?
|
| Illinois | 1 | 1997 | 462 | 0.030 |
Why?
|
| Receptor-CD3 Complex, Antigen, T-Cell | 1 | 1995 | 4 | 0.030 |
Why?
|
| Rats, Inbred WF | 1 | 1995 | 8 | 0.030 |
Why?
|
| Antibodies | 1 | 1997 | 350 | 0.030 |
Why?
|
| Life Expectancy | 1 | 2015 | 86 | 0.030 |
Why?
|
| Unsafe Sex | 1 | 2015 | 42 | 0.030 |
Why?
|
| Salvage Therapy | 1 | 1996 | 233 | 0.030 |
Why?
|
| Monitoring, Immunologic | 1 | 1995 | 17 | 0.030 |
Why?
|
| Interleukin-5 | 1 | 1995 | 36 | 0.030 |
Why?
|
| Safety | 1 | 1995 | 152 | 0.030 |
Why?
|
| Bacterial Infections | 3 | 1992 | 182 | 0.030 |
Why?
|
| Cells, Cultured | 3 | 1995 | 2818 | 0.030 |
Why?
|
| Lymphokines | 2 | 1991 | 76 | 0.030 |
Why?
|
| Extremities | 1 | 1995 | 165 | 0.030 |
Why?
|
| Blood Vessel Prosthesis | 1 | 1996 | 228 | 0.030 |
Why?
|
| Rats, Inbred ACI | 1 | 1994 | 25 | 0.030 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 1989 | 229 | 0.030 |
Why?
|
| Graft vs Host Disease | 1 | 1996 | 365 | 0.030 |
Why?
|
| Interleukin-10 | 1 | 1995 | 149 | 0.030 |
Why?
|
| Mental Health | 1 | 2015 | 162 | 0.030 |
Why?
|
| Solutions | 2 | 1991 | 85 | 0.030 |
Why?
|
| Histocompatibility Antigens | 2 | 1984 | 35 | 0.030 |
Why?
|
| Choledochostomy | 2 | 1992 | 8 | 0.030 |
Why?
|
| Immunization Schedule | 2 | 2010 | 21 | 0.030 |
Why?
|
| Thymus Gland | 1 | 1995 | 195 | 0.030 |
Why?
|
| Immunoglobulin Fab Fragments | 2 | 1991 | 81 | 0.030 |
Why?
|
| Cell Separation | 1 | 1994 | 196 | 0.030 |
Why?
|
| Immunoglobulin Fc Fragments | 3 | 2001 | 19 | 0.030 |
Why?
|
| Serum Albumin | 2 | 1988 | 130 | 0.030 |
Why?
|
| Kinetics | 2 | 1995 | 1513 | 0.030 |
Why?
|
| Cell Adhesion Molecules | 1 | 1994 | 163 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2014 | 369 | 0.030 |
Why?
|
| Cardiovascular System | 2 | 1993 | 71 | 0.030 |
Why?
|
| Immunotherapy, Adoptive | 1 | 1994 | 170 | 0.030 |
Why?
|
| Diabetic Nephropathies | 1 | 1995 | 248 | 0.030 |
Why?
|
| Common Bile Duct Diseases | 1 | 1992 | 9 | 0.030 |
Why?
|
| Saphenous Vein | 1 | 1993 | 61 | 0.030 |
Why?
|
| Uranium Compounds | 1 | 1992 | 1 | 0.030 |
Why?
|
| Uranium | 1 | 1992 | 7 | 0.030 |
Why?
|
| Hyperglycemia | 1 | 1994 | 176 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 3 | 2001 | 1047 | 0.030 |
Why?
|
| Kidney Diseases | 1 | 1996 | 418 | 0.030 |
Why?
|
| Interferon-gamma | 4 | 2000 | 444 | 0.030 |
Why?
|
| Immunoglobulin Idiotypes | 1 | 1992 | 12 | 0.030 |
Why?
|
| Ultrasonography | 2 | 1998 | 695 | 0.030 |
Why?
|
| Allopurinol | 2 | 1991 | 80 | 0.030 |
Why?
|
| Syndrome | 1 | 1993 | 446 | 0.030 |
Why?
|
| Central Nervous System | 1 | 1993 | 151 | 0.030 |
Why?
|
| Immunohistochemistry | 2 | 2005 | 1753 | 0.030 |
Why?
|
| Phosphates | 1 | 1992 | 160 | 0.030 |
Why?
|
| Communicable Diseases | 1 | 1992 | 63 | 0.030 |
Why?
|
| Gram-Negative Aerobic Bacteria | 1 | 1991 | 2 | 0.030 |
Why?
|
| Nausea | 1 | 1993 | 175 | 0.030 |
Why?
|
| Organ Preservation Solutions | 1 | 1991 | 28 | 0.030 |
Why?
|
| Abdominal Pain | 1 | 1992 | 137 | 0.030 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 1998 | 549 | 0.030 |
Why?
|
| Substance-Related Disorders | 1 | 2015 | 394 | 0.020 |
Why?
|
| Vomiting | 1 | 1993 | 193 | 0.020 |
Why?
|
| Arterial Occlusive Diseases | 1 | 1992 | 107 | 0.020 |
Why?
|
| STAT4 Transcription Factor | 2 | 2001 | 10 | 0.020 |
Why?
|
| STAT6 Transcription Factor | 2 | 2001 | 28 | 0.020 |
Why?
|
| Blood Volume | 3 | 1988 | 51 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2015 | 6501 | 0.020 |
Why?
|
| Biliary Tract Surgical Procedures | 1 | 1990 | 11 | 0.020 |
Why?
|
| Ethical Review | 1 | 1990 | 8 | 0.020 |
Why?
|
| Arteriosclerosis | 1 | 1991 | 113 | 0.020 |
Why?
|
| Renal Circulation | 1 | 1990 | 61 | 0.020 |
Why?
|
| Adoptive Transfer | 2 | 2001 | 168 | 0.020 |
Why?
|
| Hyperlipidemias | 1 | 1991 | 95 | 0.020 |
Why?
|
| Immunoglobulin M | 2 | 1988 | 154 | 0.020 |
Why?
|
| Lipoproteins | 1 | 1991 | 135 | 0.020 |
Why?
|
| Injections, Intraperitoneal | 2 | 2000 | 102 | 0.020 |
Why?
|
| In Vitro Techniques | 4 | 1994 | 989 | 0.020 |
Why?
|
| Liver Cirrhosis | 2 | 1990 | 297 | 0.020 |
Why?
|
| Lymph Nodes | 2 | 1990 | 530 | 0.020 |
Why?
|
| Dissection | 1 | 1989 | 42 | 0.020 |
Why?
|
| Cholelithiasis | 2 | 1965 | 34 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2010 | 278 | 0.020 |
Why?
|
| Embolism | 1 | 1989 | 31 | 0.020 |
Why?
|
| Portasystemic Shunt, Surgical | 1 | 1989 | 12 | 0.020 |
Why?
|
| Transfusion Reaction | 1 | 1988 | 15 | 0.020 |
Why?
|
| Esophageal and Gastric Varices | 1 | 1989 | 33 | 0.020 |
Why?
|
| Alprostadil | 1 | 1988 | 25 | 0.020 |
Why?
|
| Macaca fascicularis | 2 | 1999 | 108 | 0.020 |
Why?
|
| B7-2 Antigen | 2 | 2001 | 40 | 0.020 |
Why?
|
| Hypertension, Portal | 1 | 1989 | 47 | 0.020 |
Why?
|
| Bile Duct Neoplasms | 1 | 1989 | 79 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2013 | 1078 | 0.020 |
Why?
|
| ROC Curve | 1 | 2011 | 752 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2010 | 223 | 0.020 |
Why?
|
| Biomarkers | 1 | 1995 | 1718 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2011 | 451 | 0.020 |
Why?
|
| Cardiovascular Diseases | 1 | 1995 | 827 | 0.020 |
Why?
|
| Graft Enhancement, Immunologic | 2 | 2000 | 13 | 0.020 |
Why?
|
| Pancreatitis | 2 | 1963 | 87 | 0.020 |
Why?
|
| Nitroblue Tetrazolium | 1 | 1988 | 2 | 0.020 |
Why?
|
| Tetrazolium Salts | 1 | 1988 | 11 | 0.020 |
Why?
|
| Meningitis, Aseptic | 1 | 1988 | 8 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 1988 | 141 | 0.020 |
Why?
|
| Diagnosis, Differential | 2 | 1999 | 1565 | 0.020 |
Why?
|
| Bioethics | 1 | 2008 | 35 | 0.020 |
Why?
|
| Alkaline Phosphatase | 1 | 1988 | 132 | 0.020 |
Why?
|
| Blood Volume Determination | 2 | 1957 | 14 | 0.020 |
Why?
|
| Bile | 2 | 1998 | 57 | 0.020 |
Why?
|
| Radioisotopes | 2 | 1957 | 45 | 0.020 |
Why?
|
| Renal Dialysis | 1 | 1991 | 355 | 0.020 |
Why?
|
| Superoxide Dismutase | 1 | 1988 | 177 | 0.020 |
Why?
|
| Physical Examination | 1 | 2008 | 149 | 0.020 |
Why?
|
| Diagnosis-Related Groups | 1 | 1987 | 20 | 0.020 |
Why?
|
| Stress, Physiological | 1 | 1989 | 227 | 0.020 |
Why?
|
| Lung | 1 | 1993 | 1170 | 0.020 |
Why?
|
| Heart Diseases | 1 | 1989 | 290 | 0.020 |
Why?
|
| Lymphocyte Depletion | 2 | 1998 | 97 | 0.020 |
Why?
|
| Hepatic Veins | 2 | 2000 | 27 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1987 | 316 | 0.020 |
Why?
|
| Pulmonary Embolism | 1 | 1989 | 222 | 0.020 |
Why?
|
| T-Lymphocytes, Cytotoxic | 3 | 1992 | 315 | 0.020 |
Why?
|
| CD4 Antigens | 2 | 1999 | 83 | 0.020 |
Why?
|
| Carcinoma | 1 | 1989 | 436 | 0.020 |
Why?
|
| Medicare | 1 | 1989 | 406 | 0.020 |
Why?
|
| Hemorrhage | 1 | 1988 | 268 | 0.020 |
Why?
|
| Organ Size | 3 | 1992 | 364 | 0.020 |
Why?
|
| Seizures | 1 | 1988 | 297 | 0.020 |
Why?
|
| Clinical Trials as Topic | 2 | 1989 | 1169 | 0.020 |
Why?
|
| Cholecystectomy | 1 | 1965 | 18 | 0.020 |
Why?
|
| Iliac Artery | 1 | 1965 | 35 | 0.020 |
Why?
|
| Laparotomy | 1 | 1965 | 59 | 0.020 |
Why?
|
| Celiac Artery | 1 | 1965 | 25 | 0.020 |
Why?
|
| Radius | 1 | 2004 | 29 | 0.020 |
Why?
|
| Femur Neck | 1 | 2004 | 44 | 0.020 |
Why?
|
| Aneurysm | 1 | 1965 | 58 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2008 | 572 | 0.020 |
Why?
|
| Absorptiometry, Photon | 1 | 2004 | 99 | 0.020 |
Why?
|
| Intraoperative Period | 2 | 1998 | 90 | 0.020 |
Why?
|
| Echocardiography | 1 | 1989 | 911 | 0.020 |
Why?
|
| Isoantibodies | 2 | 1997 | 114 | 0.010 |
Why?
|
| Lumbar Vertebrae | 1 | 2004 | 148 | 0.010 |
Why?
|
| Ampulla of Vater | 1 | 1963 | 22 | 0.010 |
Why?
|
| Vascular Surgical Procedures | 1 | 1965 | 148 | 0.010 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 1984 | 213 | 0.010 |
Why?
|
| Bone Density | 1 | 2004 | 209 | 0.010 |
Why?
|
| Integrin beta3 | 1 | 2003 | 30 | 0.010 |
Why?
|
| Pancreatitis, Chronic | 1 | 1963 | 49 | 0.010 |
Why?
|
| Antigens, CD34 | 1 | 2003 | 158 | 0.010 |
Why?
|
| Kidney Tubules | 1 | 2003 | 94 | 0.010 |
Why?
|
| Crosses, Genetic | 2 | 1999 | 171 | 0.010 |
Why?
|
| Vitamin D | 1 | 2004 | 261 | 0.010 |
Why?
|
| Receptors, Tumor Necrosis Factor, Member 14 | 1 | 2001 | 7 | 0.010 |
Why?
|
| Tumor Necrosis Factor Ligand Superfamily Member 14 | 1 | 2001 | 14 | 0.010 |
Why?
|
| Anastomosis, Roux-en-Y | 2 | 1992 | 26 | 0.010 |
Why?
|
| Receptors, Virus | 1 | 2001 | 74 | 0.010 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2001 | 88 | 0.010 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 1992 | 112 | 0.010 |
Why?
|
| Surgical Procedures, Operative | 1 | 1963 | 182 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2003 | 435 | 0.010 |
Why?
|
| Cell Count | 1 | 2001 | 195 | 0.010 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2001 | 50 | 0.010 |
Why?
|
| Binding Sites, Antibody | 2 | 1992 | 49 | 0.010 |
Why?
|
| Genes, Immunoglobulin | 1 | 2001 | 111 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2001 | 307 | 0.010 |
Why?
|
| Antigen-Presenting Cells | 1 | 2001 | 139 | 0.010 |
Why?
|
| Immunity, Cellular | 1 | 2001 | 177 | 0.010 |
Why?
|
| Gene Rearrangement | 1 | 2001 | 170 | 0.010 |
Why?
|
| Blood Preservation | 1 | 1999 | 10 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2002 | 927 | 0.010 |
Why?
|
| Virus Diseases | 2 | 1992 | 97 | 0.010 |
Why?
|
| RNA, Viral | 1 | 2001 | 327 | 0.010 |
Why?
|
| Streptozocin | 1 | 1999 | 54 | 0.010 |
Why?
|
| Insulin Infusion Systems | 1 | 1999 | 36 | 0.010 |
Why?
|
| Vascular Patency | 1 | 1999 | 126 | 0.010 |
Why?
|
| Glucose Tolerance Test | 1 | 1999 | 228 | 0.010 |
Why?
|
| Fistula | 1 | 1959 | 42 | 0.010 |
Why?
|
| Iohexol | 1 | 1998 | 26 | 0.010 |
Why?
|
| Shock | 1 | 1998 | 42 | 0.010 |
Why?
|
| Cefotaxime | 1 | 1998 | 5 | 0.010 |
Why?
|
| Amoxicillin | 1 | 1998 | 13 | 0.010 |
Why?
|
| Penicillins | 1 | 1998 | 20 | 0.010 |
Why?
|
| Genes, MHC Class I | 1 | 1998 | 48 | 0.010 |
Why?
|
| Emulsions | 1 | 1998 | 19 | 0.010 |
Why?
|
| Postoperative Period | 1 | 1999 | 303 | 0.010 |
Why?
|
| Intestinal Absorption | 1 | 1998 | 124 | 0.010 |
Why?
|
| Cephalosporins | 1 | 1998 | 24 | 0.010 |
Why?
|
| Peritoneum | 1 | 1998 | 57 | 0.010 |
Why?
|
| Intraoperative Complications | 2 | 1990 | 185 | 0.010 |
Why?
|
| Amino Acid Sequence | 2 | 1992 | 2062 | 0.010 |
Why?
|
| Catheterization | 1 | 1999 | 232 | 0.010 |
Why?
|
| Aminosalicylic Acids | 1 | 1998 | 42 | 0.010 |
Why?
|
| Interleukin-4 | 1 | 1998 | 127 | 0.010 |
Why?
|
| Isotopes | 1 | 1957 | 26 | 0.010 |
Why?
|
| Chromium | 1 | 1957 | 17 | 0.010 |
Why?
|
| Cholangitis, Sclerosing | 1 | 1998 | 52 | 0.010 |
Why?
|
| Blood Group Incompatibility | 1 | 1997 | 18 | 0.010 |
Why?
|
| Herpesviridae Infections | 1 | 1997 | 46 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 1992 | 3030 | 0.010 |
Why?
|
| Public Opinion | 1 | 1997 | 43 | 0.010 |
Why?
|
| Peer Review, Research | 1 | 1997 | 36 | 0.010 |
Why?
|
| Cell Movement | 1 | 2001 | 758 | 0.010 |
Why?
|
| Knee Prosthesis | 1 | 1997 | 33 | 0.010 |
Why?
|
| Liver Failure | 1 | 1997 | 78 | 0.010 |
Why?
|
| Colectomy | 1 | 1998 | 167 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1996 | 274 | 0.010 |
Why?
|
| Angiography | 1 | 1996 | 208 | 0.010 |
Why?
|
| Belgium | 1 | 1995 | 2 | 0.010 |
Why?
|
| Avidin | 1 | 1995 | 5 | 0.010 |
Why?
|
| Ionomycin | 1 | 1995 | 21 | 0.010 |
Why?
|
| Viremia | 1 | 1995 | 54 | 0.010 |
Why?
|
| HLA-DR Antigens | 1 | 1995 | 61 | 0.010 |
Why?
|
| DNA | 1 | 2001 | 1294 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2001 | 1196 | 0.010 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1995 | 137 | 0.010 |
Why?
|
| Disease Progression | 1 | 1999 | 1531 | 0.010 |
Why?
|
| Premedication | 1 | 1994 | 54 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 1999 | 1673 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 2 | 1998 | 2601 | 0.010 |
Why?
|
| Bacteria | 1 | 1998 | 447 | 0.010 |
Why?
|
| Lectins, C-Type | 1 | 1994 | 85 | 0.010 |
Why?
|
| Prevalence | 1 | 1998 | 1239 | 0.010 |
Why?
|
| Secretory Rate | 1 | 1993 | 13 | 0.010 |
Why?
|
| Antiviral Agents | 1 | 1997 | 510 | 0.010 |
Why?
|
| Succinic Acid | 1 | 1993 | 6 | 0.010 |
Why?
|
| Contrast Media | 1 | 1998 | 1078 | 0.010 |
Why?
|
| Succinates | 1 | 1993 | 21 | 0.010 |
Why?
|
| Spectrum Analysis | 1 | 1993 | 118 | 0.010 |
Why?
|
| Mucus | 1 | 1992 | 19 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 1999 | 2232 | 0.010 |
Why?
|
| Antigen-Antibody Reactions | 1 | 1992 | 23 | 0.010 |
Why?
|
| Cholestasis | 1 | 1992 | 47 | 0.010 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 1992 | 44 | 0.010 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 1992 | 42 | 0.010 |
Why?
|
| Antibody Formation | 1 | 1993 | 171 | 0.010 |
Why?
|
| Antibody Affinity | 1 | 1992 | 38 | 0.010 |
Why?
|
| Glycoside Hydrolases | 1 | 1952 | 17 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 1992 | 145 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1992 | 173 | 0.010 |
Why?
|
| Receptors, IgG | 1 | 1992 | 52 | 0.010 |
Why?
|
| Mycoses | 1 | 1992 | 46 | 0.010 |
Why?
|
| Pancreatic Juice | 1 | 1951 | 1 | 0.010 |
Why?
|
| Vagotomy | 1 | 1951 | 12 | 0.010 |
Why?
|
| Immunoglobulin Light Chains | 1 | 1992 | 86 | 0.010 |
Why?
|
| Parasympatholytics | 1 | 1951 | 18 | 0.010 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 1992 | 131 | 0.010 |
Why?
|
| Constriction, Pathologic | 1 | 1992 | 213 | 0.010 |
Why?
|
| Pepsin A | 1 | 1991 | 5 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 1993 | 330 | 0.010 |
Why?
|
| Quaternary Ammonium Compounds | 1 | 1951 | 79 | 0.010 |
Why?
|
| Raffinose | 1 | 1991 | 24 | 0.010 |
Why?
|
| Models, Biological | 1 | 1998 | 1749 | 0.010 |
Why?
|
| Gastrectomy | 1 | 1951 | 68 | 0.010 |
Why?
|
| Crohn Disease | 1 | 1998 | 730 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 1991 | 129 | 0.010 |
Why?
|
| Immunization, Passive | 1 | 1991 | 71 | 0.010 |
Why?
|
| Peritonitis | 1 | 1991 | 29 | 0.010 |
Why?
|
| Contraindications | 1 | 1991 | 72 | 0.010 |
Why?
|
| Glutathione | 1 | 1991 | 104 | 0.010 |
Why?
|
| Neoplasms | 2 | 1993 | 2898 | 0.010 |
Why?
|
| Colitis, Ulcerative | 1 | 1998 | 711 | 0.010 |
Why?
|
| Cholecystitis | 1 | 1950 | 15 | 0.010 |
Why?
|
| Lipoprotein(a) | 1 | 1991 | 28 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 1992 | 286 | 0.010 |
Why?
|
| Plasminogen | 1 | 1991 | 41 | 0.010 |
Why?
|
| Microsurgery | 1 | 1991 | 84 | 0.010 |
Why?
|
| Epitopes | 1 | 1991 | 255 | 0.010 |
Why?
|
| Morbidity | 1 | 1991 | 148 | 0.010 |
Why?
|
| Ultrasonics | 1 | 1990 | 38 | 0.010 |
Why?
|
| Ethicists | 1 | 1990 | 20 | 0.010 |
Why?
|
| Body Weight | 1 | 1992 | 459 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 1992 | 1041 | 0.010 |
Why?
|
| Bile Duct Diseases | 1 | 1990 | 22 | 0.010 |
Why?
|
| Triglycerides | 1 | 1991 | 232 | 0.010 |
Why?
|
| Intubation | 1 | 1990 | 21 | 0.010 |
Why?
|
| Cholesterol, HDL | 1 | 1991 | 165 | 0.010 |
Why?
|
| Blood Flow Velocity | 1 | 1990 | 197 | 0.010 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 1990 | 62 | 0.010 |
Why?
|
| Radiography, Abdominal | 1 | 1990 | 71 | 0.010 |
Why?
|
| Regression Analysis | 1 | 1991 | 596 | 0.010 |
Why?
|
| Suture Techniques | 1 | 1990 | 135 | 0.010 |
Why?
|
| Rats, Inbred BN | 1 | 1988 | 37 | 0.010 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 1989 | 108 | 0.010 |
Why?
|
| Tissue Survival | 1 | 1988 | 13 | 0.010 |
Why?
|
| Cholesterol | 1 | 1991 | 356 | 0.010 |
Why?
|
| Adenosine | 1 | 1991 | 225 | 0.010 |
Why?
|
| Free Radicals | 1 | 1988 | 73 | 0.010 |
Why?
|
| Abnormalities, Multiple | 1 | 1990 | 232 | 0.010 |
Why?
|
| Kidney Function Tests | 1 | 1988 | 123 | 0.010 |
Why?
|
| Body Temperature | 1 | 1988 | 124 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 1988 | 220 | 0.000 |
Why?
|
| Sepsis | 1 | 1991 | 306 | 0.000 |
Why?
|
| Dogs | 2 | 1987 | 685 | 0.000 |
Why?
|
| Stents | 1 | 1990 | 377 | 0.000 |
Why?
|
| Blood Urea Nitrogen | 1 | 1987 | 34 | 0.000 |
Why?
|
| Immunization | 1 | 1987 | 158 | 0.000 |
Why?
|
| Parents | 1 | 1989 | 272 | 0.000 |
Why?
|
| Body Mass Index | 1 | 1989 | 770 | 0.000 |
Why?
|
| Longevity | 1 | 1984 | 51 | 0.000 |
Why?
|
| Hemodynamics | 1 | 1987 | 710 | 0.000 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 1989 | 1313 | 0.000 |
Why?
|
| Genetic Linkage | 1 | 1981 | 623 | 0.000 |
Why?
|
| Pedigree | 1 | 1981 | 966 | 0.000 |
Why?
|
| Platelet Transfusion | 1 | 1952 | 14 | 0.000 |
Why?
|
| Blood Vessels | 1 | 1952 | 94 | 0.000 |
Why?
|
| Carbon | 1 | 1952 | 80 | 0.000 |
Why?
|
| Neovascularization, Pathologic | 1 | 1952 | 353 | 0.000 |
Why?
|
| Pregnancy | 1 | 1950 | 2894 | 0.000 |
Why?
|